Developments FDA clears Eikon IND for Phase 1/2 study of EIK1006 in prostate cancer Eikon Therapeutics (NASDAQ: EIKN) has announced FDA clearance of its Investigational New Drug (IND) application for EIK1006, a novel androgen receptor antagonist, paving the way for its first-in-human Phase 1/2 study in... November 17, 2026